Quantcast

Cancer mABs Market 2019 Forecasts and Pipeline Analysis

February 21, 2014

DALLAS, February 21, 2014 /PRNewswire/ –

RnRMarketResearch.com offers cancer monoclonal antibodies market (mABs) research
reports covering pipeline analysis as well as monoclonal antibodies market forecasts in
breast cancer, colorectal cancer as well as gastric and esophageal cancers to 2019.

There are currently three monoclonal Antibody (mAb) treatments approved for metastatic
colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux
and Vectibix. The current market leader is Avastin, which generated revenues of $6.2
billion in 2012 across a number of oncology indications. While compelling late-stage
candidates are absent from the current pipeline, the anticipated rise in total prevalence
of colorectal cancer in the top eight markets may inspire further investment. Pricing
patterns for mAbs are highly favorable in the US, the largest market for colorectal
cancer, and patent expirations are not expected to have a substantial effect on any of the
featured markets. As a result of this, the report Monoclonal Antibodies Market in
Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in
Europe and Japan Ensures Market Growth
[http://www.rnrmarketresearch.com/monoclonal-antibodies-market-in-colorectal-cancer-to-2019-favorable-pricing-policy-in-the-us-and-rising-prevalence-in-europe-and-japan-ensures-market-growth-market-report.html ]
forecasts the global market to grow to a value of $5.5
billion by 2019. Key late-stage pipeline products discussed in this research include
IMC-1121B (Ramucirumab) – Eli Lilly and Company, Xilonix – Xbiotech, MetMAb (Onartuzumab)
- Hoffmann-La Roche, Anti-DR5 MoAb (Tigatuzumab) – Daiichi Sankyo, MK0646 (Dalotuzumab) -
Merck and AMG-655 (Conatumumab) – Amgen. Buy a copy of this report at
http://www.rnrmarketresearch.com/contacts/purchase?rname=136894 .

Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract.
They are often diagnosed at advanced, incurable stages due to a late onset of symptoms,
but are also associated with low survival rates in the early stages of disease. Currently
the primary treatment options are chemotherapy and surgery, which are used wherever
possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in
suitable patients with advanced gastric or gastro-esophageal junction cancer. However, the
late-stage pipelines for these indications include many promising mAb candidates which are
anticipated to enter the market during the forecast period. Additionally, current market
conditions are favorable for new mAbs, with high pricing patterns and weak impact from
biosimilar exposure. As a result of this, the report Monoclonal Antibodies Market in
Gastric and Esophageal Cancers to 2019 Crowded Late-Stage Pipelines and Favorable Market
Conditions Encourage Robust Growth
[http://www.rnrmarketresearch.com/monoclonal-antibodies-market-in-gastric-and-esophageal-cancers-to-2019-crowded-late-stage-pipelines-and-favorable-market-conditions-encourage-robust-growth-market-report.html ]
says the global market has potential to grow to a value of
$766m by 2019. Providing 34 data tables and 51 figures, a brief introduction to the two
indications, including the disease’s pathogenesis, risk factors, diagnosis and treatment
algorithms as well as in-depth analysis of Herceptin, including analysis of its safety,
efficacy, treatment patterns and strengths/weaknesses, this report is available for
purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=136895 .

The current market for breast cancer consists of five monoclonal Antibodies (mAbs),
three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2)
protein. Four are aimed at improving overall survival in the metastatic setting, and two
of these have also received further approvals in the early setting in order to improve
long-term remission rates. The market is currently led by the HER-2 inhibitor Herceptin,
which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period
from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to
achieve strong market penetration due to their appreciable incremental efficacy benefits.
Additionally, the market conditions are currently favorable towards mAbs, with a low rate
of price depreciation following patent expiry and a high rate of inflation for specialty
pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline,
the report Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel
HER-2 Targeted Therapies to Drive Robust Growth
[http://www.rnrmarketresearch.com/monoclonal-antibodies-market-in-breast-cancer-to-2019-strong-uptake-of-novel-her-2-targeted-therapies-to-drive-robust-growth-market-report.html ]
predicts global market across the leading eight countries to have a potential to grow to a
value of $10.6 billion by 2019. Promising drug candidates in the pipeline discussed in
this report include

CDX-011 (glembatumumab vedotin) – Celldex Therapeutics, Metmab (onartuzumab) – Hoffman
La Roche, Hu3S193 – Recepta Biopharma, MM-121 – Merrimack Pharmaceuticals, IMC-18F1
(Icrucumab) – Eli Lilly, Rexomun (Ertumaxomab) – Fresenius Biotech, Medi-573 (Dusigitumab)
- Medimmune, MK-0646 (Dalotuzumab) – Merck and Co and LY3012217 (Cixutumumab) – Eli Lilly.
Buy a copy of this report at
http://www.rnrmarketresearch.com/contacts/purchase?rname=127323 .

Global Cancer Monoclonal Antibodies Pipeline Analysis report gives comprehensive
insight on the various Monoclonal Antibodies being developed for the treatment of Cancer.
Research report covers all the ongoing Monoclonal Antibodies being developed in various
clinical development phases. This report enables pharmaceutical companies, collaborators
and other associated stake holders to identify and analyze the available investment
opportunity in the Cancer Monoclonal Antibodies market based upon development process.
Following parameters for each Monoclonal Antibodies drug profile in development phase are
covered in “Global Cancer Monoclonal Antibodies Pipeline Analysis
[http://www.rnrmarketresearch.com/global-cancer-monoclonal-antibodies-pipeline-analysis-market-report.html ]
” research report:

        - Drug Profile Overview
        - Alternate Names for Drug
        - Active Indication
        - Phase of Development
        - Mechanism of Action
        - Brand Name
        - Orphan Designation
        - Patent Information
        - Country for Clinical Trial
        - Owner / Originator/ Licensee/Collaborator
        - Administrative Route
        - Drug Class
        - ATC Codes

Global Cancer Monoclonal Antibodies Drug Pipeline by Clinical Phase:

        - Research: 68
        - Preclinical: 240
        - Phase-I: 112
        - Phase-I/II: 29
        - Phase-II: 73
        - Phase-II/III: 5
        - Phase-III: 31
        - Preregistration: 3
        - Marketed: 27

Buy a copy of this report at

http://www.rnrmarketresearch.com/contacts/purchase?rname=131238.

Explore Reports by Region: Africa [http://www.rnrmarketresearch.com/africa-reports ] |
Asia [http://www.rnrmarketresearch.com/asia-reports ] | Europe
[http://www.rnrmarketresearch.com/europe-reports ] | North America
[http://www.rnrmarketresearch.com/north-america-reports ] |Oceania
[http://www.rnrmarketresearch.com/oceania-reports ] | South America
[http://www.rnrmarketresearch.com/south-america-reports ]

About Us:

RnRMarketResearch.com is an online market research reports library (
http://www.rnrmarketresearch.com) of 400,000+ in-depth studies of over 5000 micro
markets. Our database includes reports by leading publishers from across the globe. We
provide 24/7 online and offline support service to our customers.

Contact:

Priyank Tiwari

TX, Dallas North – Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
sales@rnrmarketresearch.com

http://www.rnrmarketresearch.com/blog

SOURCE RnRMarketResearch.com, TBC


Source: PR Newswire



comments powered by Disqus